{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:23Z","timestamp":1788274343063,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctrv.2024.102815","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T20:07:16Z","timestamp":1724357236000},"page":"102815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review"],"prefix":"10.1016","volume":"130","author":[{"given":"Alberto","family":"Zambelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Marchi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Panizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Tinterri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102815_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline\u2606","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx365.079","article-title":"BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)","volume":"28","author":"Dalvi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0015","doi-asserted-by":"crossref","unstructured":"Breast Cancer Risk Genes \u2014 Association Analysis in More than 113,000 Women. New England Journal of Medicine. 2021;384:428\u201339. doi: 10.1056\/NEJMoa1913948.","DOI":"10.1056\/NEJMoa1913948"},{"key":"10.1016\/j.ctrv.2024.102815_b0020","unstructured":"Gori S. Linee guida AIOM CARCINOMA MAMMARIO IN STADIO PRECOCE 2023, Addendum. 2024."},{"key":"10.1016\/j.ctrv.2024.102815_b0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","article-title":"Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0030","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41388-021-01744-2","article-title":"Exploiting synthetic lethality to target BRCA1\/2-deficient tumors: where we stand","volume":"40","author":"Patel","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2024.102815_b0035","doi-asserted-by":"crossref","unstructured":"Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nature Reviews Clinical Oncology 2018 15:9. 2018;15:564\u201376. doi: 10.1038\/s41571-018-0055-6.","DOI":"10.1038\/s41571-018-0055-6"},{"key":"10.1016\/j.ctrv.2024.102815_b0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0045","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0050","first-page":"77","article-title":"A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and\/or metastatic breast cancer (EMBRACA)","author":"Litton","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102815_b0055","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0065","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0070","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM197306142882405","article-title":"Medical Assessment by a Delphi Group Opinion Technic","volume":"288","author":"Milholland","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ctrv.2024.102815_b0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jmoldx.2012.01.013","article-title":"Detection of Genomic Variations in BRCA1 and BRCA2 Genes by Long-Range PCR and Next-Generation Sequencing","volume":"14","author":"Hernan","year":"2012","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2024.102815_b0085","first-page":"220","article-title":"Multi gene panel testing for hereditary breast cancer - is it ready to be used?","volume":"92","author":"Catana","year":"2019","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.ctrv.2024.102815_b0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12687-022-00600-4","article-title":"Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review","volume":"13","author":"Gould","year":"2022","journal-title":"J Community Genet"},{"key":"10.1016\/j.ctrv.2024.102815_b0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajco.13334","article-title":"Mainstream consent programs for genetic counseling in cancer patients: A systematic review","volume":"17","author":"Scheinberg","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/gim.2014.75","article-title":"Differences in BRCA counseling and testing practices based on ordering provider type","volume":"17","author":"Cragun","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0105","first-page":"2","article-title":"Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer","author":"Kemp","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2024.102815_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.857515","article-title":"Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model","volume":"12","author":"Azzollini","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102815_b0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-22-2191","article-title":"Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine","volume":"29","author":"Asleh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102815_b0140","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/j.annonc.2020.08.458","article-title":"356TiP A phase II\/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0145","doi-asserted-by":"crossref","unstructured":"Rugo HS, Robson M, Im S-A, et al. Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study. San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. 2023;Abstract GS01-05.","DOI":"10.1158\/1538-7445.SABCS23-GS01-05"},{"key":"10.1016\/j.ctrv.2024.102815_b0150","first-page":"81","article-title":"Preservation of axillary lymph nodes compared to complete dissection in T1\u2013T2 breast cancer patients presenting 1\u20132 metastatic sentinel lymph nodes : A multicenter randomized clinical trial. Sinodar One","author":"Batra","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102815_b0155","first-page":"82","article-title":"Preservation of axillary lymph nodes compared to complete dissection in T1\u2013T2 breast cancer patients presenting 1\u20132 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One","author":"Gentile","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102815_b0160","first-page":"15","article-title":"Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer","author":"Jacobs","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102815_b0165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0170","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102511","article-title":"Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review","volume":"114","author":"Miglietta","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102815_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0190","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"A randomised phase III trial of carboplatin compared with docetaxel in BRCA1\/2 mutated and pre-specified triple negative breast cancer \u201cBRCAness\u201d subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0195","doi-asserted-by":"crossref","unstructured":"McMullen M, Karakasis K, Madariaga A, et al. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers 2020, Vol 12, Page 1607. 2020;12:1607. doi: 10.3390\/CANCERS12061607.","DOI":"10.3390\/cancers12061607"},{"key":"10.1016\/j.ctrv.2024.102815_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112944","article-title":"Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments","author":"Valenza","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.34525","article-title":"Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial","volume":"153","author":"Senkus","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0210","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0215","doi-asserted-by":"crossref","first-page":"ii16","DOI":"10.1093\/annonc\/mdv090.1","article-title":"A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)","volume":"26","author":"Roche","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102815_b0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/cer-2021-0097","article-title":"Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer","volume":"10","author":"McCrea","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ctrv.2024.102815_b0225","first-page":"1055","article-title":"Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study","volume":"22","author":"Rebbeck","year":"2016","journal-title":"Group"},{"key":"10.1016\/j.ctrv.2024.102815_b0230","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0235","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102815_b0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2022.11.036","article-title":"EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy","volume":"181","author":"Schmidt","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-10764-y","article-title":"Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer\u201c","volume":"23","author":"Deutschmann","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0250","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4048\/jbc.2013.16.3.308","article-title":"Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation","volume":"16","author":"Noh","year":"2013","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102815_b0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2214\/AJR.19.21640","article-title":"The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy","volume":"215","author":"Chapman","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2024.102815_b0260","article-title":"BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer","author":"Petrucelli","year":"2023","journal-title":"GeneReviews\u00ae Published Online First"},{"key":"10.1016\/j.ctrv.2024.102815_b0265","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.ctrv.2024.102815_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012464.pub2","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2024.102815_b0275","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMcp1714787","article-title":"Hormone Therapy for Postmenopausal Women","volume":"382","author":"Pinkerton","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102815_b0280","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/pon.5714","article-title":"BRCA mutation carriers\u2019 perceptions on postmenopausal hormone therapy: An Italian study","volume":"30","author":"Grandi","year":"2021","journal-title":"Psychooncology"},{"key":"10.1016\/j.ctrv.2024.102815_b0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:14:32Z","timestamp":1729016072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":57,"alternative-id":["S0305737224001439"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102815","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102815"}}